Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review
S Ballestri, E Romagnoli, D Arioli, V Coluccio… - Advances in …, 2023 - Springer
Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …
with a significant healthcare burden, and represent the main indications for anticoagulation …
Direct oral anticoagulants in obese patients with venous thromboembolism: results of an expert consensus panel
RP Rosovsky, E Kline-Rogers, L Lake… - The American journal of …, 2023 - Elsevier
In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …
thromboembolism treatment and prevention. A substantial proportion of patients with venous …
Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolism
JA Rueda-Camino, R Barba, S Otálora… - Thrombosis …, 2024 - Elsevier
Background There is scarce evidence on the effectiveness and safety of recommended-
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …
dose direct acting oral anticoagulants (DOACs) in obese patients with venous …
Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients
Background A paucity of data exists to support the use of factor (F) Xa inhibitors in severely
obese patients with a weight of≥ 150 kg or body mass index (BMI) of≥ 50 kg/m 2 …
obese patients with a weight of≥ 150 kg or body mass index (BMI) of≥ 50 kg/m 2 …
Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An …
P Karakasis, N Ktenopoulos, K Pamporis… - Journal of Clinical …, 2024 - mdpi.com
Background: Real-world data show limited utilization of direct oral anticoagulants (DOACs)
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …
in obese patients (body mass index [BMI]≥ 30 kg/m2) due to concerns regarding their …
Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: an updated literature review
Y Zhao, M Guo, D Li, W Xu, C Pan… - Clinical and Applied …, 2023 - journals.sagepub.com
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020
LS Costa, MM Alsultan, AL Hincapie, JJ Guo - Journal of Thrombosis and …, 2023 - Springer
The use of direct oral anticoagulants (DOACs) is widely increasing in the United States (US).
Warfarin has been the conventional anticoagulant used in the past few decades, but it has …
Warfarin has been the conventional anticoagulant used in the past few decades, but it has …
Effectiveness and safety of non-vitamin K antagonist oral anticoagulant in the treatment of patients with morbid obesity or high body weight with venous …
H Zhang, H Xie, X Wang, Z Zhu, F Duan - Medicine, 2023 - journals.lww.com
Background: Venous thromboembolism (VTE) poses a significant health risk to patients with
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
morbid obesity or high body weight. Non-vitamin K antagonist oral anticoagulants (NOACs) …
Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive …
A Knisely, MD Iniesta, S Batman, LA Meyer… - Gynecologic …, 2024 - Elsevier
Objectives To evaluate safety, efficacy, and feasibility of apixaban for postoperative venous
thromboembolism (VTE) prophylaxis following open gynecologic cancer surgery at a …
thromboembolism (VTE) prophylaxis following open gynecologic cancer surgery at a …
Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity
JD Sperry, A Loeb, MJ Smith, TB Brighton… - Journal of Thrombosis …, 2024 - Springer
Abstract Background Direct oral anticoagulants (DOACs) are the preferred treatment for
venous thromboembolism (VTE). However, DOAC use in patients with a BMI greater than 40 …
venous thromboembolism (VTE). However, DOAC use in patients with a BMI greater than 40 …